Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1371

Sort by

Sort Order Select

Journal Articles

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

Blood (2021) 137 (17): 2347–2359.

https://doi.org/10.1182/blood.2020005381

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Blood (2020) 135 (15): 1244–1254.

https://doi.org/10.1182/blood.2019003179

Published: 2020

Includes: Supplemental data

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

Hua Jiang, PhD, Abdulraouf Ramadan, PhD, Becquet Laurine, MS, Tu Szu-Wei, Hong Liu, MS, Courtney Rowan, MD, Xiaowen Liu, PhD, Huanmei Wu, PhD, Jun Wan, PhD, Sophie Paczesny, MD PhD

Blood (2019) 134 (Supplement_1): 583.

https://doi.org/10.1182/blood-2019-123821

Published: 2019

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Anthony V. Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Thomas Creasey, MBBS, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Christine J. Harrison, PhD FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 288.

https://doi.org/10.1182/blood-2019-123642

Published: 2019

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

Impact of Minimal Residual Disease Detected By Multiparameter Flow Cytometry on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission

Zoya V. Konova, Elena N. Parovichnikova, MD PhD, Irina V. Galtseva, MD PhD, Nikolay M. Kapranov, Julia O. Davydova, Mikhail Yu. Drokov, MD PhD, Maria V. Nareyko, MD, Natalia N. Popova, MD, Anna A. Dmitrova, MD, Ulyana V. Maslikova, MD, Olga S. Starikova, MD, Ekaterina I. Usikova, MD, Ekaterina D. Mikhaltsova, MD PhD, Olga M. Koroleva, MD, Vera A. Vasilyeva, MD PhD, Tatiana I. Lobanova, MD, Larisa A. Kuzmina, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2019) 134 (Supplement_1): 4562.

https://doi.org/10.1182/blood-2019-123528

Published: 2019

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

Low Serum Albumin Level Predicts the Risk of Azacitidine Early Discontinuation in MDS, CMML and 20-30% AML Patients- Results from the Polaza, the Retrospective Study of the Polish Adult Leukemia Group

Blood (2019) 134 (Supplement_1): 5421.

https://doi.org/10.1182/blood-2019-125632

Published: 2019

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Chin-Hin NG, MD MRCP, FRCPATH, MCI, Alvin Yu-Jin Ng, PhD, Benedict Yan, MBBS, Wee-Joo Chng, MBBS, PhD

Blood (2019) 134 (Supplement_1): 5177.

https://doi.org/10.1182/blood-2019-127727

Published: 2019

Journal Articles

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Jianda Hu, PhD, Yanxin Chen, MD PhD, Zhengjun Wu, Lingyan Wang, PhDMD, Jingjing Wen, Peifang Jiang, Yun Zhang, Minhui Lin, MD PhD

Blood (2019) 134 (Supplement_1): 5058.

https://doi.org/10.1182/blood-2019-127073

Published: 2019

Journal Articles

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Juan Yang, MM, Xiangxiang Zhou, MD, Ying Li, MD, Ya Zhang, MD, Xiaosheng Fang, MD, Na Chen, MD, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5065.

https://doi.org/10.1182/blood-2019-127926

Published: 2019

Journal Articles

Serum microRNA Prognostic Model and Underlying Immune Alterations in Diffuse Large B Cell Lymphoma

Sun Rui, MD, Weili Zhao, MD PhD

Blood (2019) 134 (Supplement_1): 5225.

https://doi.org/10.1182/blood-2019-128008

Published: 2019

Journal Articles

Comparison the Distinct Clinical Outcome with TP53 Mutation Status in MDS and AML :an Retrospective Study

Xinrong Xiang, MD, Yang Ou, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 5405.

https://doi.org/10.1182/blood-2019-124622

Published: 2019

Journal Articles

Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B-Cell Lymphoma - a Single Center Experience

Ashok K Vaid, MDDM, Suman S Karanth, MD DNB, Aseem Khurana, MBBS ,M.Ed, Nitin Sood, MDFRCPath,MRCP, Ashok Sen, MD, Gautam Dheeraj, MD, Bhuvan Chugh, DNB, Saurabh Mishra, MD DNB

Blood (2019) 134 (Supplement_1): 5350.

https://doi.org/10.1182/blood-2019-126414

Published: 2019

NARROW

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

The different flavors and splices of MCL

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

IL-33 Therapy Prevents Acute Lung Injury after Transplantation Via IL-9-Producing Type 2 Innate Lymphoid Cells Induction

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Impact of Minimal Residual Disease Detected By Multiparameter Flow Cytometry on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Low Serum Albumin Level Predicts the Risk of Azacitidine Early Discontinuation in MDS, CMML and 20-30% AML Patients- Results from the Polaza, the Retrospective Study of the Polish Adult Leukemia Group

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Whole Exome Sequencing of Relapsed Double-Mutated CEBPA Acute Myeloid Leukemia Identified Mutated KIT and WNT10A As a Potential Co-Mutation with Negative Impact on Prognosis

Targeting Nucleolin for Reversal of Chemotherapy Resistance in Acute Lymphoblastic Leukemia

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Serum microRNA Prognostic Model and Underlying Immune Alterations in Diffuse Large B Cell Lymphoma

Comparison the Distinct Clinical Outcome with TP53 Mutation Status in MDS and AML :an Retrospective Study

Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B-Cell Lymphoma - a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only